Cargando…

Efficacy and safety of topically applied therapeutic ammonia oxidising bacteria in adults with mild-to-moderate atopic dermatitis and moderate-to-severe pruritus: a randomised, double-blind, placebo-controlled, dose-ranging, phase 2b trial

BACKGROUND: Topical anti-inflammatory therapy is a cornerstone of treatment for atopic dermatitis (AD). However, many unmet needs remain with existing therapies. B244 is a live topical biotherapeutic being tested for the reduction of pruritus and improvement of eczema signs in patients with AD. We a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Silverberg, Jonathan I., Lio, Peter A., Simpson, Eric L., Li, Connie, Brownell, Daniel R., Gryllos, Ioannis, Ng-Cashin, Judith, Krueger, Todd, Swaidan, Victoria R., Bliss, Robin L., Kim, Hyun D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314159/ https://www.ncbi.nlm.nih.gov/pubmed/37396805 http://dx.doi.org/10.1016/j.eclinm.2023.102002

Ejemplares similares

Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD
por: Hall, Rebecca, et al.
Publicado: (2021)

Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild‐to‐moderate atopic dermatitis
por: Eichenfield, Lawrence F., et al.
Publicado: (2020)

Correction to: Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD
por: Hall, Rebecca, et al.
Publicado: (2021)

Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families
por: Simpson, Eric L., et al.
Publicado: (2018)

Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis
por: Yosipovitch, G., et al.
Publicado: (2019)

Release of cervical muscular tension improved severe pruritus in moderate-to-severe atopic dermatitis: A case series
por: Hosono, Shusaku, et al.
Publicado: (2020)

Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis
por: Silverberg, Jonathan I., et al.
Publicado: (2021)

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial
por: Silverberg, Jonathan I., et al.
Publicado: (2020)

Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis
por: SILVERBERG, Jonathan I., et al.
Publicado: (2021)

Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
por: Bernardo, Diana, et al.
Publicado: (2023)

Emerging Methods to Objectively Assess Pruritus in Atopic Dermatitis
por: Smith, Mary Patricia, et al.
Publicado: (2019)

Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years
por: Luger, Thomas A., et al.
Publicado: (2022)

Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate‐to‐severe atopic dermatitis from the BREEZE‐AD7 Phase 3 randomized trial
por: Wollenberg, A., et al.
Publicado: (2021)

Determining Severity Strata for Three Atopic Dermatitis Patient-Reported Outcome Questionnaires: Defining Severity Score Ranges for the Worst Pruritus Numerical Rating Scale and the Atopic Dermatitis Symptom and Impact Scales (ADerm-SS and ADerm-IS)
por: Silverberg, Jonathan I., et al.
Publicado: (2022)

Nitrification and beyond: metabolic versatility of ammonia oxidising archaea
por: Wright, Chloe L., et al.
Publicado: (2023)

Cultivation of ammonia-oxidising archaea on solid medium
por: Klein, Timothy, et al.
Publicado: (2022)

Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
por: Kuznik, Andreas, et al.
Publicado: (2017)

Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice
por: Gooderham, Melinda J., et al.
Publicado: (2023)

Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Association of Moderate–Severe Atopic Dermatitis with Dental Anomalies
por: Tan, Sean Y., et al.
Publicado: (2022)

Safety of tralokinumab in adult patients with moderate‐to‐severe atopic dermatitis: pooled analysis of five randomized, double‐blind, placebo‐controlled phase II and phase III trials
por: Simpson, Eric L., et al.
Publicado: (2022)

Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial
por: Blauvelt, Andrew, et al.
Publicado: (2021)

Neuroimmunological Mechanism of Pruritus in Atopic Dermatitis Focused on the Role of Serotonin
por: Kim, Kwangmi
Publicado: (2012)

The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus
por: Rerknimitr, Pawinee, et al.
Publicado: (2017)

Exploring Immune Development in Infants With Moderate to Severe Atopic Dermatitis
por: Hulshof, Lies, et al.
Publicado: (2018)

Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate‐to‐severe disease
por: Sims, Jonathan T., et al.
Publicado: (2021)

Psychometric validation and responder definition of the sleep disturbance numerical rating scale in moderate‐to‐severe atopic dermatitis
por: Puelles, J., et al.
Publicado: (2021)

Apremilast Use for Moderate-to-Severe Atopic Dermatitis in Pediatric Patients
por: Saporito, Rachael C., et al.
Publicado: (2016)

Correction to: Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Dupilumab in patients with moderate to severe atopic dermatitis and multiple sclerosis
por: Esposito, Maria, et al.
Publicado: (2022)

Small-scale variation of ammonia oxidisers within intertidal sediments dominated by ammonia-oxidising bacteria Nitrosomonas sp. amoA genes and transcripts
por: Duff, Aoife M., et al.
Publicado: (2017)

Oxidative stress as a treatment target in atopic dermatitis: The role of furfuryl palmitate in mild-to-moderate atopic dermatitis
por: Hebert, Adelaide A.
Publicado: (2020)

Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis
por: Silverberg, Jonathan I., et al.
Publicado: (2021)

Neurogenic markers of the inflammatory process in atopic dermatitis: relation to the severity and pruritus
por: Teresiak-Mikołajczak, Ewa, et al.
Publicado: (2013)

Transcutaneous Slowly Depolarizing Currents Elicit Pruritus in Patients with Atopic Dermatitis
por: RUKWIED, Roman, et al.
Publicado: (2020)

Pathomechanism of Pruritus in Psoriasis and Atopic Dermatitis: Novel Approaches, Similarities and Differences
por: Kaczmarska, Agnieszka, et al.
Publicado: (2023)

Ocular surface disease is common in moderate‐to‐severe atopic dermatitis patients
por: Achten, Roselie E., et al.
Publicado: (2022)

Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial
por: Reich, Kristian, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vkd4ogbcb0h0f27tl3ghcdqnr9